AI Article Synopsis
- The Ppargc1a gene produces various PGC-1α isoforms that play a crucial role in controlling energy production in mitochondria and helping cells adapt to different conditions.
- Specific isoforms of PGC-1α can offer protective benefits in various disease models when expressed in mice.
- The summary highlights how factors like transcription, splicing, translation, protein stability, and activity of Ppargc1a contribute to its diverse functions in the body.
Article Abstract
The peroxisome proliferator-activated receptor γ coactivator-1α (Ppargc1a) gene encodes several PGC-1α isoforms that regulate mitochondrial bioenergetics and cellular adaptive processes. Expressing specific PGC-1α isoforms in mice can confer protection in different disease models. This SnapShot summarizes how regulation of Ppargc1a transcription, splicing, translation, protein stability, and activity underlies its multifaceted functions. To view this SnapShot, open or download the PDF.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cell.2022.03.027 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anticonvulsant effects of pentoxifylline on seizures induced by pentylenetetrazole and maximal electroshock in male mice: The role of the nitrergic pathway.
IBRO Neurosci Rep
December 2024
Pharmacology Department, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Introduction: Epilepsy remains a challenge, with one-third of patients experiencing refractory seizures despite current anti-seizure medications. The nitrergic system, which involves nitric oxide (NO) and NO synthase (NOS) enzymes, plays a complex role in seizure pathophysiology. Pentoxifylline (PTPh), an FDA-approved phosphodiesterase inhibitor, has anticonvulsant effects; however, its relationship with the pathway is unclear.
View Article and Find Full Text PDFOncogenic activation of in cancers: Emerging targeted therapies in precision oncology.
Genes Dis
March 2025
Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH 44106, USA.
Phosphoinositide 3-kinases (PI3Ks) are heterodimers consisting of a p110 catalytic subunit and a p85 regulatory subunit. The gene, which encodes the p110α, is the most frequently mutated oncogene in cancer. Oncogenic mutations activate the PI3K pathway, promote tumor initiation and development, and mediate resistance to anti-tumor treatments, making the mutant p110α an excellent target for cancer therapy.
View Article and Find Full Text PDFIdentification of crucial drought-tolerant genes of barley through comparative transcriptomic analysis and yeast-based stress assay.
Front Genet
December 2024
College of Agronomy, Qingdao Agricultural University, Qingdao, China.
Drought is a persistent and serious threat to crop yield and quality. The identification and functional characterization of drought tolerance-related genes is thus vital for efforts to support the genetic improvement of drought-tolerant crops. Barley is highly adaptable and renowned for its robust stress resistance, making it an ideal subject for efforts to explore genes related to drought tolerance.
View Article and Find Full Text PDFSelective JAK1 inhibitors and the therapeutic applications thereof: a patent review (2016-2023).
Expert Opin Ther Pat
December 2024
Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, P. R. China.
Introduction: The family of Janus kinases (JAKs) consists of four intracellular non-receptor tyrosine kinases: JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2). Among these four subtypes, JAK1 is the only isoform that can form heterodimers with all three JAKs, and JAK1 dysfunction can lead to inflammation and severe autoimmune diseases. Interest in JAK1 inhibitors has grown tremendously, and the number of inhibitors targeting JAK1 continues to rise annually.
View Article and Find Full Text PDFProbing the Protein Kinases' Cysteinome by Covalent Fragments.
Angew Chem Int Ed Engl
December 2024
Goethe-Universitat Frankfurt am Main Fachbereich 14 Biochemie Chemie und Pharmazie, Institute for Pharmaceutical Chemistry, GERMANY.
Protein kinases are important drug targets, yet specific inhibitors have been developed for only a fraction of the more than 500 human kinases. A major challenge in designing inhibitors for highly related kinases is selectivity. Unlike their non-covalent counterparts, covalent inhibitors offer the advantage of selectively targeting structurally similar kinases by modifying specific protein side chains, particularly non-conserved cysteines.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!